Showing 3831-3840 of 7027 results for "".
- BeautyHealth Introduces Hydrafacial x JLo Beauty Boosterhttps://practicaldermatology.com/news/beautyhealth-introduces-the-hydrafacial-x-jlo-beauty-booster/2461369/The BeautyHealth Company is rolling out the Hydrafacial x JLo Beauty Booster . “I'm so excited to partner with Hydrafacial to create the new JLo Beauty Booster,” says founder of JLo Beauty Jennifer Lopez in a news release. “Hydrafacial is one of my favorite treatme
- Galderma, NBCF Partner to Launch Campaign Elevating Skin Stories of Breast Cancer Survivorshttps://practicaldermatology.com/news/galderma-nbcf-partner-to-launch-campaign-elevating-skin-stories-of-breast-cancer-survivors/2461366/Galderma is continuing its partnership with National Breast Cancer Foundation Inc. (NBCF) with a new campaign that elevates the skin stories of breast cancer survivors. Galderma is featuring the personal stories and treatment journeys of breast cancer survivors who received Re
- Positive Topline Results from Pivotal Phase 3 Trial of Arcutis Biotherapeutics' Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-results-from-pivotal-phase-3-trial-of-arctuis-biotherapeutics-roflumilast-foam-in-scalp-and-body-psoriasis/2461359/Topline results from the ARRECTOR Pivotal Phase 3 trial evaluating Arcutis Biotherapeutics, Inc.'s roflumilast foam 0.3% were positive for the treatment of adults and adolescents with scalp and body psoriasis. The study met its co-primary endpoints of S-
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). &ldquo
- Meet EMFACE From BTLhttps://practicaldermatology.com/news/meet-emface-from-btl/2461350/BTL is taking on the minimally invasive facial aesthetic category with the launch of EMFACE. Emface simultaneously emits both
- Meet the Cast of Allergan Aesthetics and BOTOX Cosmetic's New 'See Yourself' Campaignhttps://practicaldermatology.com/news/meet-the-cast-of-allergan-aesthetics-and-botox-cosmetics-new-see-yourself-campaign/2461344/Allergan Aesthetics is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX Cosmetic 'See Yourself' campaign. A After receiving nearly 20,000 submis
- Baby Dove Doubles Down Efforts to Close the Maternal Care Gap with #DearDoula and Greater Investment in Black Birth Equity Fundhttps://practicaldermatology.com/news/baby-dove-doubles-down-efforts-to-close-the-maternal-care-gap-with-deardoula-and-greater-investment-in-black-birth-equity-fund/2461342/Baby Dove is expanding the Black Birth Equity Fund, launching a new informative series called #DearDoula, and reinforcing existing strategic partnerships to help close the significant gap in care and health outcomes for Black mothers and their babies. "As a brand that encourages al
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recom
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point s
- EADV News: Tape Strip Test May Predict Eczema Risk in Babieshttps://practicaldermatology.com/news/eadv-news-tape-strip-test-may-predict-eczema-risk-in-babies/2461329/An immune biomarker in newborns may predict the subsequent onset and severity of paediatric atopic eczema, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The Barrier dysfunction in Atopic newBorns (BABY) study analyzed a c